The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).

Olulade Ayodele1
Howard J Cabral2,3
David McManus4
Susan Jick1,5

1Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA; 2Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA; 3Biostatistics and Research Design Program, Boston University Clinical and Translational Science Institute, Boston, MA, USA; 4Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA; 5Boston Collaborative Drug Surveillance Program, Lexington, MA, USA

Background: Many men receive 5-alpha reductase inhibitors (5ARIs) for ongoing treatment of benign prostatic hyperplasia (BPH). The increased risk of cardiovascular complications with 5ARIs has been documented in BPH studies and the occurrence of cerebral venous thrombosis, presumably due to increased estrogen level following 5ARI use, was described in multiple case reports. The objective of this study was to determine if 5ARIs with or without alpha blockers (AB) were associated with an increased risk of venous thromboembolism (VTE) in males with BPH.

Methods: We conducted a nested case–control study among a population of men ages 40–79 who received at least one 5ARI or AB prescription for treatment of BPH between 1995 and 2015 in the UK-based Clinical Practice Research Datalink GOLD. Cases of incident VTE (pulmonary embolism [PE] or deep venous thrombosis [DVT]) and matched controls were identified from this population. We used descriptive analyses and conditional logistic regression to evaluate the risk of VTE in users of 5ARIs compared to users of ABs.

Results: For 5ARI only users, the adjusted odds ratios (aORs), (95% CI) for VTE were 1.51 (0.98–2.32) in current 5ARI users and 1.23 (0.70–2.17) in recent/distant past, compared to AB only users. However, the aOR (95% CI) in men who had 50 or more current 5ARI prescriptions compared to users of ABs only was higher: 2.29 (1.14–4.63). For 5ARI with AB use, the aORs, (95% CI) for VTE were 1.16 (0.64–2.10) in current 5ARI+AB users and 1.93 (0.71–5.25) in recent/distant past, compared to AB only users. The aOR (95% CI) in men who had 50 or more current 5ARI+AB prescriptions compared to users of ABs only was 1.65 (0.64–4.26).

Conclusion: Current use of 5ARI, particularly long-term use, is associated with an increased risk of incident idiopathic VTE compared to patients treated with AB use only.

Keywords: 5ARI, BPH, VTE, alpha blocker

Introduction

Benign prostatic hyperplasia (BPH) is a highly prevalent condition among older men, which impacts quality of life, sexual function, and genitourinary health. Close to 30% of men over the age of 50 have BPH.1,2 The two main drug classes prescribed for management of BPH symptomatic relief are alpha-blockers (ABs) and 5-alpha reductase inhibitors (5ARIs) either alone or in combination.2,3

To the best of our knowledge, this is the first study to evaluate the risk of venous thromboembolism (VTE) in relation to the use of 5ARIs. The closest comparisons available are in studies that evaluated the risk of VTE and cardiovascular outcomes...
associated with testosterone use and androgen deprivation therapy. Studies of cardiovascular safety in men who take 5ARIs are limited and have yielded conflicting results. While some studies suggest dihydroteosterone (DHT) reduces cardiovascular disease risk, others suggest that androgen (DHT and testosterone) suppression increases the incidence of myocardial infarction (MI), stroke and diabetes.4–7 Other studies found an increased short-term risk of VTE in testosterone users.8 Since 5ARIs prevent the formation of DHT, the active form of testosterone,9,10 it is possible that 5ARIs decrease the risk of developing VTE. Multiple case reports have indicated 5ARI as a potential cause of cerebral venous thrombosis potentially due to increased serum estrone and estradiol levels.11,12 Similarly, multiple studies have found an increased risk of gynecomastia among users of 5ARIs,13–25 possibly due to an increase in estrone and estradiol levels.9,26–28 These hormones promote thrombus development and can thus increase VTE risk.29–32

5ARIs have become widely used for management of BPH; thus, it is important to understand the potential long-term adverse or beneficial effects of their use in this population that is typically older, has multiple comorbidities and many known VTE risk factors that could confound the 5ARI-VTE relationship. To our knowledge, these hormonal effects are not anticipated with ABs. In this study, we evaluated the effects of 5ARIs compared to an active comparator group, AB use (to control for confounding by indication), on the risk of VTE in a population-based sample of men aged 40–79 with BPH in the United Kingdom.

Methods
This was a nested case–control study conducted using Clinical Practice Research Datalink (CPRD) GOLD data from years 1995–2015. CPRD GOLD is an ongoing longitudinal database, established in 1987, of over 400 general practices in the UK. It contains data on a representative sample of more than 10 million UK patients recorded by general practitioners (GPs) using standard software and coding systems. In addition to patient demographic information, participating GPs record anonymized data that includes medical diagnoses, prescriptions issued in primary care (including dosage and quantity), details of hospital stays and specialist referrals, laboratory tests, lifestyle details [such as smoking, body mass index (BMI), alcohol use] and deaths. Large validation studies have demonstrated the accuracy and completeness of data captured in the CPRD GOLD for use in pharmacoepidemiologic research.33–35 This study is based in part on data from the CPRD obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. This study was approved by the Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare Products Regulatory Agency database research (protocol no: 17_148R), and the protocol was made available to the journal reviewers upon request.

The study population was comprised of 91,115 men aged 40–79 in CPRD GOLD, who had a diagnosis of BPH identified using Read codes and who had received at least one prescription for a 5ARI (finasteride or dutasteride) and/or an AB (alfuzosin, doxazosin, indoramin, prazosin, tamsulosin and terazosin) for the treatment of BPH during 1995–2015.

Outcome
Cases were men with an incident idiopathic VTE [Read code for Deep Venous Thrombosis (DVT) or Pulmonary Embolism (PE)] after the electronic medical record start date. We required all cases to have one or more years of information in the CPRD before the index date, defined as the date of the first VTE diagnosis in the cases or the matched date for controls. Cases with cancer (except non-melanoma skin cancer) or history of VTE prior to the index date were excluded. Idiopathic VTE was defined as VTE in the absence of a code for another proximate cause (including immobility, prolonged hospitalization, fractures, multiple traumas, orthopedic surgery involving long bones or pelvis and, other major surgery) within 90 days prior to the first VTE diagnosis. Cases were required to have 2 or more prescriptions for anticoagulants (including unfractionated heparin, low-molecular-weight heparins and fondaparinux) present on or within 90 days after the VTE diagnosis date to increase the specificity of the case definition.

Control Selection
From the base population, we matched up to four controls to each eligible case on index date (same index date as their matched case), year of birth (±3 years), general practice attended and the year the patient’s CPRD record started (±3 years). The same inclusion and exclusion criteria used in cases were applied to controls.
Exposure- 5ARI and AB Use

A patient was considered exposed if they had at least one prescription for a 5ARI in their record prior to the index date. Patients were assigned to one of the following mutually exclusive exposure categories based on the closest prescription prior to the index date: 5ARI only, or 5ARI + AB (on the same date). We also evaluated 5ARI exposure according to timing of use: We categorized exposure as current use of 5ARI if the length of the last prescription continued to the index date (where use was defined as the prescription length + 30 days). Recent use was defined as use that ended between 30 and 119 days prior to the index date. Past use was defined as use that ended between 120 days and less than 305 days prior to the index date, and distant past use was defined as use that ended 305 days or more prior to the index date.

In addition, we examined the number of 5ARI prescriptions recorded before the index date (0, 1–6, 7–24, 25–49, 50+) and the total cumulative dose of 5ARI in micrograms recorded before the index date (0, 1–999, 1000–9999, 10,000+) in current users, to assess whether heavier use was associated with elevated risk of VTE. To calculate the cumulative dose for each study participant, we multiplied the number of pills in each prescription by their strength and summed all prescriptions before the index date.

The referent group was comprised of patients whose most recent prescription prior to the index date was for an AB only, regardless of how long before the index date it was received.

Covariates

Information on covariates was derived from the patient records and included known or suspected risk factors for VTE: age, smoking status (never, past, current and unknown), calendar time (to capture secular trends in VTE risk and 5ARI or AB use), BMI (<24.9, 25–29.9, ≥30 kg m-2, unknown) and comorbidities- (including diabetes [with/without end-organ damage], chronic kidney disease (CKD), cerebrovascular disease, cardiovascular disease [MI, heart failure, peripheral vascular disease], chronic obstructive pulmonary disease, dementia, hemiplegia, peptic ulcer disease, acquired immune deficiency syndrome, liver disease, connective tissue disease including vasculitis, AIDS, alcohol abuse disorders, hypertension, coagulopathies, and phlebitis). We defined each comorbidity based on the presence of at least one Read code prior to the index date. We then calculated a Charlson Comorbidity Index (CCI) score for each patient and categorized them into 3 groups: 1–3, 4 and 5+.

Finally, we classified each case and control by whether they switched between the study drugs (ABs and 5ARIs) before the index date (yes/no) and by the duration of BPH prior to the index date (<5 years and 5 + years).

Data Analysis

We calculated crude and adjusted odds ratios (OR) and 95% confidence intervals (95% CI) to estimate the risk of VTE in patients ever and currently exposed to 5ARIs (with or without AB) at the index date in comparison with patients ever exposed to AB only using conditional logistic regression modelling for matched pairs using PROC LOGISTIC using SAS statistical software (version 9.4, Cary, NC: SAS Institute. Inc).

We evaluated covariates that were structurally deemed to be confounders, based on directed acyclic graphs (history of phlebitis, diabetes, COPD, CVD, obesity, smoking, CKD, hyperlipidemia, CCI score) to determine if they were confounders of the 5ARI-VTE association. Each covariate was added to the model one at a time, and the relationship with the exposure and outcome was assessed.

If the addition of the covariate altered the measure of association by at least 10%, it was included in the adjusted model. The final model included BMI, CKD, switching between 5ARIs and ABs, cardiovascular and cerebrovascular disease separately and all other comorbidities were summarized by CCI scores. We stratified the results by age, BPH duration, switching between AB and 5ARI, obesity status and CCI score to assess effect measure modification (EMM).

We assessed the potential for residual confounding in sensitivity analyses restricted to “healthy” cases and controls (ie those with no diagnosis for VTE related comorbidities such as cerebrovascular disease, coronary heart disease, heart failure, COPD, autoimmune disorders, diabetes and hypertension prior to the index date). We also conducted sensitivity analyses where we defined current use as use that ended within 14 days, recent: 15–119 days, past: 120–305 days and distant past: >305 days. Finally, we also conducted sensitivity analyses where we compared 5ARI exposure to AB only by recency of use, ie current, recent or past AB use, instead of any use.
Results

We identified 266 idiopathic VTE cases who met all study criteria to which we matched 1061 controls. There were 64 (24%) cases and 218 (21%) controls exposed to a 5ARI only at the index date, 33 (12%) cases and 130 (12%) controls exposed to a 5ARI+AB and 169 (64%) cases and 713 (67%) controls exposed to an AB only at the index date.

The distribution of potential VTE risk factors and patient characteristics, as well as the bivariable OR estimates and associated 95% CIs, are presented in Table 1. VTE cases were more likely than controls to have a history of cardiovascular disease, chronic kidney disease, phlebitis, COPD, smoking and a higher body mass index (BMI >30+). Sixty-two percent of cases had at least one comorbidity compared with 56% of controls and 37% of cases had a Charlson comorbidity index score ≥ 5 compared with 31% of controls.

5ARI users were older, more likely to have cardiovascular and renal disease, and to have a longer BPH duration compared to 5ARI + AB users or AB only users. See Table 2.

The OR of VTE was slightly elevated in ever users of 5ARIs only (adjusted OR [aOR] 1.41 (95% CI 0.97–2.07)) and ever users of 5ARI+AB (aOR 1.27, 95% CI 0.72–2.21) compared to AB only users. When we evaluated current 5ARI use, the risk of VTE was slightly higher (aOR 1.51, 95% CI 0.98–2.32) compared to AB only use. The numbers were small in all analyses and all CIs included 1.0. The OR for current use of 5ARI + AB compared to AB only use and for non-current use of 5ARIs only remained close to the null (aOR =1.16, 95% CI 0.64–2.10), and (1.23, 95% CI 0.70–2.17), respectively (Table 3). In the models where we evaluated current 5ARI use, with or without concurrent AB use, the results were attenuated (aOR= 1.38 (0.93–2.06)) compared to models with 5ARI use alone versus AB (Table 4).

When we classified 5ARI exposure by number of prescriptions and cumulative dose to evaluate the presence of a dose response relationship, the risk of VTE was highest in the highest use categories (Table 5): aOR =2.29, 95% CI 1.14–4.63 for current 5ARI users with 50 or more prescriptions and aOR=2.15, 95% CI 1.18–3.92 for cumulative dose of 10,000 mcg and higher compared to AB users.

In stratified analyses, there was no evidence of effect modification by age [Supplement 1].

We evaluated BMI as a potential mediator on the causal pathway between 5ARI use and VTE. However, we did not observe any material change or reduction in the effect size between the crude OR (OR Current 5ARI only use = 1.36, 95% CI 0.92–2.03) and the BMI adjusted OR (OR Current 5ARI only use=1.39, 95% CI 0.93–2.07). We observed an increased risk of VTE (aOR=2.7, 95% CI 1.1–6.7) in current 5ARI only users who were obese (BMI≥30 kg/m²) compared to AB users [Supplement 2] but the cell sizes were small. For men who were not obese (BMI<30 kg/m²), the effect size was smaller (aOR=1.4, 95% CI 0.9–2.2), and the result is consistent with a null effect. The pattern was similar in models where we evaluated the number and cumulative dose of 5ARI prescriptions.

We evaluated effect measure modification by CCI score. Due to the small cell sizes, we evaluated any current 5ARI use (ie with or without concurrent AB use) compared to AB use. The risk of VTE increased with higher comorbidity scores (test for trend p=0.01). For current users of 5ARI±AB compared to AB use, the aOR of VTE was 1.38, 95% CI (0.93–2.06); for men with a CCI score of 1–3 the aOR was 0.94, 95% CI (0.48–1.82); for men with a score of 4 the aOR was 1.53, (95% CI 0.71–3.28) and for men with a score of 5+ the aOR was 1.57 (95% CI 0.90–2.75) [Table 4].

Redefining current use in a sensitivity analysis as 5ARI use that ended within 14 days (instead of 30) of the index date did not materially change the magnitude of the effect estimates [Supplement 3].

There was no material difference in results when we conducted sensitivity analyses to assess current 5ARI use compared to current AB use [Supplement 4], nor were the results meaningfully different from the main analysis when we conducted sensitivity analysis restricted to the VTE cases with no history of CKD, vasculitis or coagulopathy (adjusted OR 1.66, 95% CI 0.97–2.83 for current 5ARI use and 1.39, 95% CI 0.70–2.76 for current 5ARI+AB use, compared to AB) [data not shown], or when we excluded cases with diagnoses of hypertension, diabetes, hyperlipidemia, cerebrovascular disease, coronary heart disease, heart failure, COPD, autoimmune disorders, and severe liver disease prior to the index date.

Discussion

The results of our study on this population of men aged 40–79 years with treated BPH suggest that current 5ARI use, particularly at high cumulative dose, is associated with an increased risk of incident idiopathic VTE when compared to patients treated with ABs only; aOR for any
Table 1 Characteristics and Bivariate Odds Ratios in Venous Thromboembolism Cases and Matched Controls; BPH Patients Aged 40–79 in CPRD GOLD 1995–2015

| Characteristic                                | Cases (n=266) | Controls (n=1061) | OR     | 95% CI  |
|-----------------------------------------------|---------------|-------------------|--------|---------|
| **Age at Index Date (years)**                 |               |                   |        |         |
| <60                                           | 23 (8.6)      | 87 (8.2)          | NA a   | NA a    |
| 60–69                                         | 66 (24.7)     | 267 (25.1)        | NA a   | NA a    |
| 70–74                                         | 60 (22.5)     | 233 (21.9)        | NA a   | NA a    |
| ≥75                                           | 118 (44.2)    | 478 (44.9)        | NA a   | NA a    |
| Mean ± Std. Dev                               | 73.2 ±8.4     | 73.2±8.3          | NA a   | NA a    |
| **Index Year**                                |               |                   |        |         |
| 1995–1999                                     | 6 (2.3)       | 24 (2.3)          | NA a   | NA a    |
| 2000–2004                                     | 37 (13.9)     | 148 (13.9)        | NA a   | NA a    |
| 2005–2009                                     | 95 (35.6)     | 377 (35.4)        | NA a   | NA a    |
| 2010–2015                                     | 129 (48.3)    | 516 (48.5)        | NA a   | NA a    |
| **Length of Record Before Index Date (Years)**|               |                   | 0.96   | 0.93–0.99|
| Mean ± Std. Dev                               | 18.5±4.6      | 19.4±4.3          |        |         |
| **BMI**                                       |               |                   |        |         |
| <25 kg/m²                                     | 60 (22.6)     | 307 (28.9)        | Reference | Reference |
| 25–30 kg/m²                                   | 111 (41.7)    | 469 (44.2)        | 1.22   | 0.85–1.75 |
| >30 kg/m²                                     | 75 (28.2)     | 218 (20.6)        | 1.86   | 1.25–2.78 |
| Unknown                                       | 20 (7.5)      | 67 (6.3)          | 1.61   | 0.88–2.97 |
| Mean ± Std. Dev                               | 26.0±8.75     | 25.3±7.74         | 1.01   | 1.00–1.03 |
| **Smoking Status**                            |               |                   |        |         |
| Non-Smoker                                    | 121 (45.5)    | 442 (41.7)        | Reference | Reference |
| Current smoker                                | 27 (10.2)     | 145 (13.7)        | 0.66   | 0.41–1.06 |
| Past-Smoker                                   | 103 (38.7)    | 404 (38.1)        | 0.93   | 0.68–1.26 |
| Unknown                                       | 15 (5.6)      | 70 (6.6)          | 0.75   | 0.39–1.44 |
| **Comorbidities at Index Date**               |               |                   |        |         |
| Hypertension                                  | 74 (27.8)     | 266 (25.1)        | 1.16   | 0.85–1.60 |
| Diabetes                                      | 30 (11.3)     | 156 (14.7)        | 0.70   | 0.45–1.09 |
| Diabetes End Organ Damage                     | 11 (4.1)      | 43 (4.1)          | 1.01   | 0.49–2.08 |
| Hyperlipidemia                                | 40 (15.0)     | 143 (13.5)        | 1.17   | 0.77–1.76 |
| Alcohol use                                   | 7 (2.6)       | 21 (2.0)          | 1.35   | 0.56–3.23 |
| Chronic Obstructive Pulmonary Disease         | 37 (13.9)     | 109 (10.3)        | 1.46   | 0.96–2.21 |
| Epilepsy                                      | 8 (3.0)       | 21 (2.0)          | 1.66   | 0.66–4.20 |
| Autoimmune                                    | 38 (14.3)     | 115 (10.8)        | 1.37   | 0.93–2.04 |
| Cardiovascular b                              | 122 (45.9)    | 395 (37.2)        | 1.53   | 1.14–2.07 |
| Cardiovascular                               | 122 (45.9)    | 395 (37.2)        | 1.53   | 1.14–2.07 |
| Stroke or TIA                                 | 41 (15.4)     | 142 (13.4)        | 1.19   | 0.80–1.76 |
| Myocardial Infarction                         | 22 (8.3)      | 102 (9.6)         | 0.83   | 0.51–1.37 |
| Peripheral Vascular Disease                  | 21 (7.9)      | 64 (6.0)          | 1.34   | 0.79–2.26 |
| Chronic Heart Failure                         | 24 (9.0)      | 62 (5.8)          | 1.67   | 1.00–2.80 |
| Other                                         | 14 (5.2)      | 25 (2.4)          | 1.46   | 0.98–2.20 |
| Chronic Kidney Disease                        | 80 (30.1)     | 205 (19.3)        | 2.00   | 1.42–2.79 |
| Severe CKD                                     | 37 (13.9)     | 103 (9.7)         | 1.63   | 1.04–2.55 |
| Vasculitis                                    | NR            | NR                | 1.00   | 0.11–8.95 |
| Coagulopathy                                  | 7 (2.6)       | 18 (1.7)          | 1.62   | 0.65–4.06 |
| Phlebitis                                     | 31 (11.7)     | 53 (5.0)          | 2.85   | 1.72–4.74 |

(Continued)
Table 1 (Continued).

|                              | Cases (n=266) | Controls (n=1061) | OR    | 95% CI           |
|------------------------------|---------------|-------------------|-------|-----------------|
| Dementia                     | 7 (2.6)       | 20 (1.9)          | 1.37  | 0.57–3.27       |
| Ulcer                        | 27 (10.2)     | 96 (9.0)          | 1.16  | 0.72–1.85       |
| Non-melanoma skin cancer     | 22 (8.3)      | 79 (7.4)          | 1.13  | 0.68–1.86       |
| Prostatectomy                | 40 (15.0)     | 143 (13.5)        | 1.16  | 0.77–1.74       |
| Charlson Comorbidity Index Score |              |                   |       |                 |
| CCI: 1–3                     | 108 (40.6)    | 507 (47.8)        | Reference | Reference |
| CCI: 4                       | 59 (22.2)     | 225 (21.2)        | 1.54  | 1.02–2.32       |
| CCI: 5+                      | 99 (37.2)     | 329 (31.0)        | 1.90  | 1.26–2.88       |
| CCI Score                    | 4.18±2.07     | 3.96±1.89         | 1.10  | 1.04–1.17       |
| Time Between BPH Diagnosis and Index Date | | | | |
| Less than 1 year             | 33 (12.4)     | 126 (11.9)        | Reference | Reference |
| 1 – <2 years                 | 25 (9.4)      | 104 (9.8)         | 0.92  | 0.51–1.64       |
| 2 – <5 years                 | 72 (27.1)     | 310 (29.2)        | 0.89  | 0.56–1.41       |
| 5 – <10 years                | 90 (33.8)     | 350 (33.0)        | 0.98  | 0.63–1.54       |
| ≥10 years                    | 46 (17.3)     | 171 (16.1)        | 1.03  | 0.62–1.70       |
| Exposure at Index Date       |               |                   |       |                 |
| AB only                      | 169 (63.5)    | 713 (67.2)        | Reference | Reference |
| 5ARI + AB                    | 33 (12.4)     | 130 (12.3)        | 1.09  | 0.70–1.69       |
| 5ARI                         | 64 (24.1)     | 218 (20.6)        | 1.26  | 0.90–1.77       |
| Recency of Exposure Closest to Index Date | | | | |
| AB only                      | 169 (63.5)    | 713 (67.2)        | Reference | Reference |
| Current use of 5ARI          | 70 (26.3)     | 250 (23.6)        | 1.21  | 0.86–1.69       |
| Recent/Past use of 5ARI      | 5 (1.9)       | 21 (2.0)          | 1.02  | 0.38–2.74       |
| Distant past use of 5ARI     | 22 (8.3)      | 77 (7.3)          | 1.22  | 0.73–2.05       |
| Switch Between AB and ARI Before Index Date | | | | |
| No                           | 183 (68.8)    | 727 (68.5)        | Reference | Reference |
| Yes                          | 83 (31.2)     | 334 (31.5)        | 0.99  | 0.73–1.35       |

Notes: *Matching factor. †Cardiovascular disease includes Ischemic heart disease, Acute coronary syndrome, Stroke, pericardial disease, pulmonary hypertension, peripheral vascular disease, chronic heart failure, coronary heart disease.

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; NA, not applicable; NR, not reportable; Current use, 5ARI use less than 30 days prior to the index date; Recent use, 5ARI use 31–119 days prior to the index date; Past use, 5ARI use 120–305 days prior to the index date; Distant past use, 5ARI use more than 305 days prior to the index date.

current 5ARI use 1.51 (0.98–2.32). The increased risk of VTE was higher in patients who had 50 or more 5ARI prescriptions [aOR: 2.29 (1.14–4.63)]. This finding persisted regardless of stratification by various potential confounders, further supporting the finding.

Our study was designed to control for confounding by indication (BPH); we used an active comparator of AB users rather than a non-exposed referent to control for confounding by severity of BPH. Since men with BPH have increased activity of the 5 alpha reductase enzyme, they may have a different risk of VTE compared to men without BPH, regardless of treatment; thus, it was important to use an active comparator. However, users of 5ARIs only in this study were less healthy than users of AB only or of 5ARI+AB; thus, residual confounding by indication may be present and could explain the elevated risk found in this study. We must also consider, however, the possibility that the active comparator group (AB users) also had an increased baseline risk of VTE, and that 5ARI use confers an even stronger risk of VTE than suggested by this study.

Many men in this study were at high risk of VTE, that is, they had multiple comorbidities and cardiovascular risk factors. Our analysis stratified by CCI showed that the risk
Table 2 Characteristics of Exposed and Unexposed Controls at Index Date: BPH Patients Aged 40–79 in CPRD GOLD 1995–2015

|                              | 5ARI Exposed (n=218) | 5ARI+AB Exposed (n=130) | AB Exposed (n=713) |
|------------------------------|----------------------|--------------------------|-------------------|
| **Age at Index Date (years)**|                      |                          |                   |
| <60                          | 10 (4.6)             | 5 (3.9)                  | 67 (11.1)         |
| 60–69                        | 50 (22.9)            | 39 (30.0)                | 148 (24.6)        |
| 70–74                        | 34 (15.6)            | 29 (22.3)                | 135 (22.4)        |
| ≥75                          | 124 (56.9)           | 57 (43.9)                | 252 (41.9)        |
| Mean ± Std. Dev              | 75.1±8.0             | 73.6±7.6                 | 72.5±8.5          |
| **Index Year**               |                      |                          |                   |
| 1995–1999                    | 6 (2.8)              | NR                       | 18 (2.5)          |
| 2000–2004                    | 34 (15.6)            | 9 (6.9)                  | 105 (14.7)        |
| 2005–2009                    | 77 (35.3)            | 35 (26.9)                | 261 (36.6)        |
| 2010–2015                    | 101 (46.3)           | 86 (66.2)                | 329 (46.1)        |
| **BMI**                      |                      |                          |                   |
| <24 kg/m²                    | 74 (33.9)            | 28 (21.5)                | 205 (28.8)        |
| 25–30 kg/m²                  | 90 (41.3)            | 64 (49.2)                | 315 (44.2)        |
| >30 kg/m²                    | 40 (18.4)            | 33 (25.4)                | 145 (20.3)        |
| Unknown                      | 14 (6.4)             | 5 (3.9)                  | 48 (6.7)          |
| **Smoking Status**           |                      |                          |                   |
| Non-Smoker                   | 92 (42.2)            | 61 (46.9)                | 289 (40.5)        |
| Current smoker               | 28 (12.8)            | 11 (8.5)                 | 106 (14.9)        |
| Past-Smoker                  | 80 (36.7)            | 53 (40.8)                | 271 (38.0)        |
| Unknown                      | 18 (8.3)             | 5 (3.9)                  | 47 (6.6)          |
| **Comorbidities**            |                      |                          |                   |
| Hypertension                 | 49 (22.5)            | 39 (30.0)                | 178 (25.0)        |
| Diabetes                     | 30 (13.8)            | 21 (16.2)                | 105 (14.7)        |
| End organ damage             | 7 (3.2)              | 8 (6.2)                  | 28 (3.9)          |
| Hyperlipidemia               | 28 (12.8)            | 18 (13.8)                | 97 (13.6)         |
| Cardiovascular               | 93 (42.7)            | 41 (31.5)                | 261 (36.6)        |
| CVA or TIA                   | 34 (15.6)            | 15 (11.5)                | 93 (13)           |
| Myocardial Infarction        | 29 (13.3)            | 11 (8.5)                 | 62 (8.7)          |
| CHF                          | 22 (7.8)             | 10 (6.1)                 | 54 (6.1)          |
| PVD                          | 17 (7.8)             | 5 (3.8)                  | 42 (5.9)          |
| Alcohol Abuse                | 7 (3.2)              | NR                       | 10 (1.4)          |
| COPD                         | 22 (10.1)            | 12 (9.2)                 | 75 (10.5)         |
| Epilepsy                     | 7 (3.2)              | NR                       | 14 (2.0)          |
| Autoimmune                   | 22 (10.1)            | 12 (9.2)                 | 81 (11.4)         |
| CKD                          | 57 (26.1)            | 25 (19.2)                | 123 (17.3)        |
| Severe CKD                   | 23 (10.6)            | 22 (16.9)                | 58 (8.1)          |
| Vasculitis                   | NR                   | NR                       | NR                |
| Coagulopathy                 | NR                   | NR                       | 12 (1.7)          |
| Phlebitis                    | 7 (3.2)              | 6 (4.6)                  | 40 (5.6)          |
| Prostatectomy                | 34 (15.6)            | 15 (11.5)                | 94 (13.2)         |
| Dementia                     | 7 (3.2)              | 3 (2.3)                  | 10 (1.4)          |
| Ulcer                        | 20 (9.2)             | 18 (13.8)                | 58 (8.1)          |
| Non-melanoma skin cancer     | 17 (7.8)             | 9 (6.9)                  | 53 (7.4)          |

(Continued)
Table 2 (Continued).

| Charlson Comorbidity Index Score | 5ARI Exposed (n=218) | 5ARI+AB Exposed (n=130) | AB Exposed (n=713) |
|----------------------------------|----------------------|------------------------|-------------------|
| CCI: 1–3                         | 98 (45.0)            | 54 (41.5)              | 355 (49.8)        |
| CCI: 4                           | 44 (20.2)            | 31 (23.9)              | 150 (21.0)        |
| CCI: 5+                          | 76 (34.9)            | 45 (34.6)              | 208 (29.2)        |

Time between BPH diagnosis and Index Date

| Less than 1 year | 24 (11.0) | 14 (10.8) | 88 (12.3) |
| 1 – <2 years     | 17 (7.8)  | 20 (15.4) | 67 (9.4)  |
| 2 – <5 years     | 66 (30.3) | 29 (22.3) | 215 (30.2) |
| 5 – <10 years    | 62 (28.4) | 46 (35.4) | 242 (33.9) |
| ≥10 years        | 49 (22.5) | 21 (16.2) | 101 (14.2) |

Notes: Categorical variables are presented as N (%). Continuous variables are presented as Mean (SD).
Abbreviation: NR, not reportable.

of VTE increased with higher comorbidity scores (test for trend p=0.01) similar to a previous study, which found that patients with a CCI score of 4 and higher had a higher risk of VTE. This supports the notion that there may be residual confounding in this study and that higher morbidity could explain the increased risk of VTE in 5ARI users.

To the best of our knowledge, this is the first study to evaluate the risk of VTE in relation to the use of 5ARIs. The closest comparisons available are in studies that evaluated the risk of VTE associated with testosterone use. A study by Baillargeon et al found that testosterone therapy was not associated with an increased risk of VTE in middle-aged and older men with testosterone deficiency. Since 5ARI inhibits the production of DHT, a metabolite of testosterone, we expect 5ARI to have an opposing effect on VTE compared to testosterone therapy, i.e., an increase in VTE risk.

There is growing evidence that DHT has cardiovascular protective properties and an anti-inflammatory effect that promotes endothelial health, thus with inhibition of

Table 3 Crude and Adjusted Odds Ratios and Distribution of Exposure at Index Date Among Venous Thromboembolism Cases and Matched Controls: BPH Patients Aged 40–79 in CPRD GOLD 1995–2015

| Any Exposure at Index Date | Cases (n=266) | Controls (n=1061) | Crude OR | Adjusted* OR |
|---------------------------|---------------|-------------------|----------|--------------|
| AB only                   | 169 (63.5%)   | 713 (67.2%)       | Reference| Reference    |
| 5ARI                      | 64 (24.1%)    | 218 (20.6%)       | 1.26 (0.90–1.77) | 1.41 (0.97–2.07) |
| 5ARI + AB                 | 33 (12.4%)    | 130 (12.3%)       | 1.09 (0.70–1.69) | 1.27 (0.72–2.21) |

| Recency by Exposure at Index Date | Cases (n=266) | Controls (n=1061) | Crude OR | Adjusted* OR |
|----------------------------------|---------------|-------------------|----------|--------------|
| AB only                          | 169 (63.5%)   | 713 (67.2%)       | Reference| Reference    |
| Current use of 5ARI              | 44 (16.5%)    | 138 (13.0%)       | 1.36 (0.92–2.03) | 1.51 (0.98–2.32) |
| Recent/Past/Distant past use of 5ARI | 20 (7.5%) | 80 (7.5%) | 1.07 (0.63–1.82) | 1.23 (0.70–2.17) |
| Current use of 5ARI + AB         | 26 (9.8%)     | 112 (10.6%)       | 0.99 (0.61–1.62) | 1.16 (0.64–2.10) |
| Recent/Past/Distant past use of 5ARI + AB | 7 (2.6%) | 18 (1.7%) | 1.67 (0.67–4.15) | 1.93 (0.71–5.25) |

Notes: Variables are presented as N (%). *Adjusted for cardiovascular disease, chronic kidney disease, switch, body mass index and CCI. Conditional on the matching factors.
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; Current use, 5ARI use less than 30 days prior to the index date; Recent use, 5ARI use 31–119 days prior to the index date; Past use, 5ARI use 120–305 days prior to the index date; Distant past use, 5ARI use more than 305 days prior to the index date.
Table 4 Crude and Adjusted Odds Ratios for the Association Between 5ARI Exposure and VTE Stratified by Charlson Comorbidity Index Score; BPH Patients Aged 40–79 in CPRD GOLD 1995–2015

| Comorbidity Score | Cases (n=266) | Controls (n=1061) | Crude OR (95% CI) | Adjusted* OR (95% CI) |
|-------------------|---------------|-------------------|-------------------|-----------------------|
| All Patients      |               |                   |                   |                       |
| Recency of any 5ARI |               |                   |                   |                       |
| AB only           | 169 (63.5)    | 713 (67.2)        | 1.0 (reference)   | 1.0 (reference)        |
| Current use of 5ARI ± AB | 70 (26.3)    | 250 (23.6)        | 1.21 (0.86–1.69)  | 1.38 (0.93–2.06)       |
| Recent/Past/Distant past use of 5ARI ± AB | 27 (10.2)    | 98 (9.2)          | 1.18 (0.74–1.88)  | 1.37 (0.82–2.30)       |
| Comorbidity Score: 1–3 |                 |                   |                   |                       |
| AB only           | 80 (74.1)     | 355 (70.0)        | 1.0 (reference)   | 1.0 (reference)        |
| Current use of 5ARI ± AB | 16 (14.8)    | 107 (21.1)        | 0.67 (0.37–1.19)  | 0.94 (0.48–1.82)       |
| Recent/Past/Distant past use of 5ARI ± AB | 12 (11.1)    | 45 (8.9)          | 1.19 (0.60–2.35)  | 1.49 (0.72–3.08)       |
| Comorbidity Score: 4 |                 |                   |                   |                       |
| AB only           | 35 (59.3)     | 150 (66.7)        | 1.0 (reference)   | 1.0 (reference)        |
| Current use of 5ARI ± AB | 17 (28.8)    | 57 (25.5)         | 1.27 (0.66–2.44)  | 1.53 (0.71–3.28)       |
| Recent/Past/Distant past use of 5ARI ± AB | 7 (11.9)   | 18 (8.0)          | 1.66 (0.64–4.27)  | 1.62 (0.55–4.73)       |
| Comorbidity Score: 5 |                 |                   |                   |                       |
| AB only           | 54 (54.6)     | 208 (63.2)        | 1.0 (reference)   | 1.0 (reference)        |
| Current use of 5ARI ± AB | 37 (37.4)   | 86 (26.1)         | 1.66 (1.02–2.70)  | 1.57 (0.90–2.75)       |
| Recent/Past/Distant past use of 5ARI ± AB | 8 (8.1)    | 35 (10.6)         | 0.88 (0.39–2.01)  | 0.75 (0.31–1.80)       |

Notes: Variables are presented as N (%). *Adjusted for age, cardiovascular disease, chronic kidney disease, switch, and body mass index. Conditional on the matching factors.

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; Current use, 5ARI use less than 30 days prior to the index date; Recent use, 5ARI use 31–119 days prior to the index date; Past use, 5ARI use 120–305 days prior to the index date; Distant past use, 5ARI use more than 305 days prior to the index date.

DHT production (such as is seen with 5ARI use), an increase in VTE risk among 5ARI users compared to non-users is biologically plausible.

While the mechanisms for developing VTE and atherothrombotic outcomes are not exactly the same, some parallels can be drawn from studies that evaluated the risk of cerebrovascular disease, MI, and strokes. A previous study showed that androgen-deprivation therapies (ADTs) such as gonadotropin-releasing hormone agonists and orchiectomy, which reduce the serum levels of testosterone and DHT, increase the risk of MI and stroke.41,42 Similarly, a study by Yeap et al43 showed that higher DHT levels were associated with a decreased risk of IHD mortality and optimal testosterone levels were associated with a reduced risk of all-cause mortality. However, studies examining the relationship of 5ARI use to cardiovascular outcomes have had conflicting findings.5,6,43–49

One of the arguments against a causal explanation for the increased risk of VTE with 5ARI use in previous studies is that ADTs that cause harmful metabolic effects and increase thrombotic events tend to suppress a broad spectrum of androgens. Since 5ARIs only suppress DHT, they cannot significantly increase cardiovascular risk through this mechanism.41,50 In this study, we found an increased risk with heavy use of 5ARIs, perhaps because the suppression of DHT with low-dose 5ARI use is not sufficient to cause harmful thrombotic effects, while at higher cumulative dose, it may activate prothrombotic pathways that are comparable to other ADTs. BPH patients have high levels of DHT, which is corrected to the physiologic range with 5ARI use.51–53 With higher doses, further suppression of DHT levels may have a negative effect. This may explain why the users of 5ARIs with >50 prescriptions or >10,000 mcg of 5ARI...
Table 5 Crude and Adjusted Odds Ratios and Distribution of Exposure at Index Date by Number of Prescriptions and Cumulative Dose (Mcg) of 5ARI Among Venous Thromboembolism Cases and Matched Controls: BPH Patients Aged 40–79 in CPRD GOLD 1995–2015

|                          | Cases (n=266) | Controls (n=1061) | Crude OR | Adjusted* OR |
|--------------------------|---------------|------------------|----------|--------------|
| **Number of Prescriptions by Timing at Index Date** |               |                  |          |              |
| AB only                  | 169 (63.5%)   | 713 (67.2%)      | Reference| Reference    |
| 5ARI                     |               |                  |          |              |
| Current 1–24             | 20 (7.5%)     | 64 (6.1%)        | 1.32 (0.77–2.29) | 1.50 (0.84–2.69) |
| Current 25–49            | 8 (3.0%)      | 36 (3.4%)        | 0.89 (0.39–2.04) | 0.85 (0.36–2.04) |
| Current 50+              | 16 (6.0%)     | 38 (3.6%)        | 1.78 (0.97–3.26) | 2.29 (1.14–4.63) |
| Recent/Past/Distant past use | 20 (7.5%)   | 80 (7.5%)        | 1.07 (0.63–1.82) | 1.23 (0.70–2.18) |
| 5ARI + AB                |               |                  |          |              |
| Current 1–24             | 8 (3.0%)      | 60 (5.7%)        | 0.52 (0.23–1.18) | 0.62 (0.25–1.52) |
| Current 25–49            | 10 (3.8%)     | 26 (2.5%)        | 1.74 (0.79–3.83) | 1.96 (0.82–4.67) |
| Current 50+              | 8 (3.0%)      | 26 (2.5%)        | 1.30 (0.58–2.92) | 1.65 (0.64–4.26) |
| Recent/Past/Distant past use | 7 (2.6%)    | 18 (1.7%)        | 1.75 (0.70–4.35) | 2.03 (0.74–5.56) |
| **Cumulative Dose of Prescriptions (mcgs) by Timing at Index Date** |               |                  |          |              |
| AB only                  | 169 (63.5%)   | 713 (67.2%)      | Reference| Reference    |
| 5ARI                     |               |                  |          |              |
| Current 1–999            | 5 (1.9%)      | 19 (1.8%)        | 1.13 (0.38–3.36) | 1.32 (0.43–4.05) |
| Current 1000–9999        | 17 (6.4%)     | 70 (6.6%)        | 0.99 (0.56–1.76) | 1.09 (0.60–1.98) |
| Current 10,000+          | 22 (8.3%)     | 49 (4.6%)        | 1.95 (1.12–3.41) | 2.15 (1.18–3.92) |
| Recent/Past/Distant past use | 20 (7.5%)   | 80 (7.5%)        | 1.06 (0.62–1.80) | 1.22 (0.69–2.16) |
| 5ARI + AB                |               |                  |          |              |
| Current 1–999            | 5 (1.9%)      | 5 (0.5%)         | 4.03 (1.16–14.00) | 5.47 (1.45–20.58) |
| Current 1000–9999        | 13 (4.9%)     | 52 (4.9%)        | 1.09 (0.56–2.12) | 1.22 (0.58–2.57) |
| Current 10,000+          | 8 (3.0%)      | 55 (5.2%)        | 0.58 (0.26–1.30) | 0.67 (0.27–1.64) |
| Recent/Past/Distant past use | 7 (2.6%)    | 18 (1.7%)        | 1.66 (0.67–4.14) | 1.90 (0.70–5.19) |

Notes: Variables are presented as N (%). *Adjusted for cardiovascular disease, chronic kidney disease, switch, body mass index and CCI. Conditional on the matching factors.

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; current use, 5ARI use less than 30 days prior to the index date; Recent use, 5ARI use 31–119 days prior to the index date; Past use, 5ARI use 120–305 days prior to the index date; Distant past use, 5ARI use more than 305 days prior to the index date.

in our study were at an increased risk of VTE, while in patients at lower cumulative doses/number of prescriptions, there was a near null effect.

Our study has several strengths. First, we used a longitudinal primary care database with high accuracy of diagnoses and completeness of drug prescription data. We found known risk factors to be independently associated with the risk of VTE (ie, history of fractures, surgeries, cardiovascular comorbidities, phlebitis, CKD, extended hospitalizations), providing confidence in the quality of the data and its ability to detect associations between BPH treatments and risk of VTE. Second, we controlled our analyses for a range of potential confounders, including age, BMI, cardiovascular disease, CKD and others, using the CCI score. Since information on diseases and drug exposures was recorded in the absence of a study hypothesis, there is no risk of recall bias. By excluding men who had insufficient history in their medical record before study start in both cases and controls, we reduced the risk of including men with recurrent, rather than incident, VTE. Furthermore, the mean record length before the index date in this study was greater than 18 years enabling us to assess the potential risks and benefits of long-term drug use.

There are some limitations to consider. We did not have access to information regarding medication adherence because drug information in the CPRD reflects written, not...
pharmacy dispensed or used prescriptions. However, patients with repeat (2+) prescriptions are more likely to have filled and used the medications and the risk of VTE was higher in these patients, suggesting that non-use of prescribed medications did not bias the results.

Objective measures of BPH severity are not captured in the CPRD GOLD data, beyond the duration of BPH. Therefore, we were unable to assess the impact of BPH severity on the results. However, we minimized the heterogeneity of BPH severity by only including patients with 5ARI and/or AB prescriptions. Our study results suggest that the duration of BPH is not an independent risk factor for VTE and that stratification by BPH duration does not change the interpretation of our findings. We considered whether patients receiving both ABs and 5ARIs instead of one or the other could be at higher risk of VTE, but our findings did not support this.

In conclusion, our study provides evidence that high cumulative dose of 5ARIs may increase the risk of incident VTE in men with BPH who are free of major VTE risk factors (eg cancers, fractures, surgeries and strong cardiovascular risk factors), potentially due to excessive inhibition of the anti-inflammatory properties of DHT in promoting endothelial health and preventing thrombogenesis.

Since BPH is a common condition in men and 5ARIs are primary drug treatments, further studies of 5ARI use are warranted to inform use in every day clinical practice.

Disclosure
Dr David McManus reports grants, personal fees from Bristol Myers Squibb, grants, personal fees from Pfizer, grants from Boehringer Ingelheim, personal fees from Flexcon, non-financial support from Apple, personal fees from Aavana, grants from Philips, personal fees, non-financial support from Fitbit, grants from Heart Rhythm Society, non-financial support from Samsung, personal fees from Rose Consulting, outside the submitted work. The authors report no other conflicts of interest in this work.

References
1. Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang J. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. *Int J Clin Pract*. 2007;61(9):1437–1445. doi:10.1111/j.1742-1241.2007.01508.x
2. Emberton M, Marberger M, De La Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the prostate research on behaviour and education (PROBE) survey. *Int J Clin Pract*. 2008;62:18. doi:10.1111/j.1742-1241.2007.01635.x
3. Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. *BJU Int*. 2011;107:876–880. doi:10.1111/j.1464-410X.2010.10041.x
4. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. *J Urol*. 2009;181(5):1998–2008. doi:10.1016/j.juro.2009.01.047
5. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. *J Natl Cancer Inst*. 2010;102(1):39–46. doi:10.1093/jnci/djp404
6. Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. *Eur Urol*. 2014;65(4):704–709. doi:10.1016/j.eururo.2013.02.002
7. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Brenner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. *Arch Intern Med*. 2007;167:1252. doi:10.1001/archinte.167.12.1252
8. Walker RF, Zakai NA, Maclehole RF, et al. Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. *JAMA Intern Med*. 2020;180(2):190–197. doi:10.1001/jamainternmed.2019.5135
9. Yao S, Tille C, Kristal AR, et al. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. *Cancer Causes Control*. 2011;22:1121–1131. doi:10.1007/s10552-011-9787-7
10. Simon T, De Jonge-canonico MBY, Oger E, et al. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. *J Thromb Haemost*. 2006;4:71–76. doi:10.1111/j.1538-7836.2005.01693.x
11. Choi BK, Cheon K, Cho B-H, Jung JW, Yi K. Cerebral venous sinus thrombosis associated with dutasteride use. *Yonsei Med J*. 2020;61(6):553–555. doi:10.3349/ymj.2020.61.6.553
12. Kang DW, Jeong HG, Kim HR, et al. Finasteride induced cerebral venous thrombosis. *J Korean Neurol Assoc*. 2015;33:238–240. doi:10.17340/jkna.2015.3.22
13. Mansouri P, Farshi S, Safar F. Finasteride-induced gynecomastia. *Indian J Dermatol Venereol Leprol*. 2009;75:309–310. doi:10.4103/0378-6323.51273
14. Ferrando J. Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride. *Arch Dermatol*. 2004. doi:10.1001/archderm.138.4.543
15. Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. *N Engl J Med*. 2002;345:138. doi:10.1056/nejm19960912355111
16. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. *Urology*. 2002;60(3):434–441. doi:10.1016/S0090-4295(01)01905-2
17. Desgrandchamps F, Drousy S, Irani J, Saussine C, Comenducci A. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. *BJU Int*. 2006;98(1):83–88. doi:10.1111/j.1464-410X.2006.06241.x
18. Debruyne F, Barkin J, Van EP, Reis M, Tammela TLJ, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. *Eur Urol*. 2004;46(4):488–495. doi:10.1016/j.eururo.2004.05.008
19. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. 1992. *J Urol*. 2002;167(2 Pt 2):1102–1107. doi:10.1016/s0022-5347(02)00349-4
20. Andriole GL, Kirby R. Safety and tolerability of the dual inhibitor dutasteride in the treatment of benign prostatic hyperplasia. *Eur Urol*. 2003;44(1):82–88. doi:10.1016/S0302-2838(03)00198-2
21. Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular risk factors associated with venous thromboembolism. *JAMA Cardiol*. 2019;4(2):163. doi:10.1001/jamacardio.2018.4537
22. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med*. 2003;349(3):215–224. doi:10.1056/nejmoa030660

23. Miller JA, Pramanik B, Gilhooley P. Waxing and waning gynecomas- tia: an indication of noncompliant use of prescribed medication. *South Med J*. 1999;92(6):615–617. doi:10.1097/00007611-199906000-00012

24. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. *J Am Acad Dermatol*. 2006;55(6):1014–1023. doi:10.1016/j.jaad.2006.05.007

25. Grino P, Stoner E, Andriole GL, et al. Finasteride for the treatment and control of benign prostatic hyperplasia: summary of Phase III controlled studies. *Eur Urol*. 1994;25(SUPPL. 1):24–28. doi:10.1159/000475328

26. Trath AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. *J Sex Med*. 2011;8(3):872–884. doi:10.1111/j.1743-6109.2010.02157.x

27. Shenoy NK, Prabhakar SM. Finasteride and male breast cancer; does the MHRA report show a link? *J Cutan Aesthet Surg*. 2010;3(2):102–105. doi:10.4103/0974-2077.69022

28. Tsuji Y, Nakayama T, Bono K, Kitamura M, Imafuku I. Two cases of stroke associated with the use of finasteride, an approved drug for male-pattern hair loss in Japan. *Rinsho Shinkeigaku*. 2014;54:423–428. doi:10.5692/clincalneurorl.54.423

29. Sacco S, Ricci S, Degn D, Carolei A. Migrantre in women: the role of hormones and their impact on vascular diseases. *J Headache Pain*. 2012;13(3):177–189. doi:10.1007/s10194-012-0424-y

30. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. *Arteriolescler Thromb Vasc Biol*. 2002;22(2):201–210. doi:10.1161/01.ATV.0000028026.44318.8f

31. Parkin L, Sharple K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK general practice research database. *BMJ*. 2011;342(april21 2):d2139–d2139. doi:10.1136/bmj.d2139

32. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Chanier KS. Testosterone as a protective factor against atherosclerosis - immunomodulation and influence upon plaque development and stability. *J Endocrinol*. 2003;178:373–380. doi:10.1677/0022-2581.007037

33. García Rodriguez LA, Pérez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. *Br J Clin Pharmacol*. 1998;45(5):419–425. doi:10.1046/j.1365-2125.1998.00701.x

34. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RDT. Validation of the diagnosis of venous thromboembolism in general practice database studies. *Br J Clin Pharmacol*. 2000;49:591–596. doi:10.1046/j.1365-2125.2000.00199.x

35. Huerta C, Johansson S, Wallander MA, García Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. *Arch Intern Med*. 2007;167:935. doi:10.1001/archinte.167.9.935

36. Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. *J Clin Epidemiol*. 1994;47(11):1245–1251. doi:10.1016/0895-4356(94)00129-5

37. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-8

38. Ording AG, Horváth-Puho E, Lash TL, et al. Prostate cancer, comorbidities, and the risk of venous thromboembolism: a cohort study of 44,035 Danish prostate cancer patients,1995–2011. *Cancer*. 2015;121(20):3692–3699. doi:10.1002/cncr.29535
